Opinion

Video

The Evolving Landscape of Newly Diagnosed Multiple Myeloma

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

Patel provides an overview of recent developments in treating newly diagnosed multiple myeloma patients. The distinction between transplant-eligible vs ineligible is blurring, with some fit patients choosing to defer transplant. Triplet regimens have shifted to quadruplet regimens incorporating anti-CD38 monoclonal antibodies like daratumumab or isatuximab. Studies like GRIFFIN and PERSEUS show quadruplet regimens improve responses over triplets for both standard-risk and high-risk transplant-eligible patients.

For transplant-ineligible/frail patients, lenalidomide-bortezomib-dexamethasone (RVd) remains an option, but daratumumab-lenalidomide-dexamethasone (DRd) based on the MAIA trial may provide an even longer treatment-free interval. For high-risk transplant-ineligible patients, a quadruplet approach with RVd plus daratumumab is also being studied.

A key goal of therapy has become attaining minimal residual disease (MRD) negativity, which is associated with improved progression-free and overall survival. The depth of response seen with quadruplet regimens may help support regulatory approval of MRD as a biomarker for novel agents.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Alex Herrera, MD
Ajay K. Nooka, MD, MPH, FACP
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Bertram Yuh, MD, MISM, MSHCPM